Alida Biosciences is at the forefront of next-generation epigenetic analysis, focusing on the multiplexed detection of RNA modifications. Their flagship product, the EpiPlex™ Library Prep Kit, utilizes a proximity barcoding-based assay to simultaneously profile critical RNA modifications such as m6A and inosine in mRNA and long non-coding RNA. This innovative approach allows researchers to obtain detailed information about the identity, location, and relative quantity of RNA modifications, all while integrating full RNA sequencing data. The technology is designed to streamline workflows, requiring minimal RNA input and enabling the analysis of multiple samples in a single experiment, thus enhancing efficiency and reducing variability in results.

The company emphasizes the importance of understanding the epitranscriptome, which encompasses all naturally occurring RNA modifications that play vital roles in various biological processes, including cancer progression and drug resistance. Alida Biosciences aims to provide tools that not only facilitate basic and clinical research but also pave the way for new therapeutic strategies targeting RNA modification pathways. Their proprietary bioinformatics pipeline further supports researchers by simplifying the interpretation of complex genomic data, making it accessible for diverse applications across pharmaceuticals, diagnostics, and agricultural sciences.

United States

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Alida Biosciences

Company Details